List of Excipients in Branded Drug ARISTADA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alkermes Inc	ARISTADA	aripiprazole lauroxil	65757-401	POLYSORBATE 20	2030-10-26
Alkermes Inc	ARISTADA	aripiprazole lauroxil	65757-401	SODIUM CHLORIDE	2030-10-26
Alkermes Inc	ARISTADA	aripiprazole lauroxil	65757-401	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS	2030-10-26

ARISTADA Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 20, 2026

ARISTADA is Alkermes plc's long-acting injectable formulation of aripiprazole lauroxil for schizophrenia in adults. Its commercial differentiation depends on a depot suspension system, multiple dosing intervals, a prefilled delivery format, and the separate ARISTADA INITIO initiation product. The excipient system is relatively conventional, but the manufacturing process, particle attributes, injectability requirements, device presentation, and clinical dosing regimen create barriers that are more significant than the ingredient list alone suggests.

What is ARISTADA and how does its formulation work?

ARISTADA contains aripiprazole lauroxil, a prodrug of aripiprazole, as an extended-release intramuscular suspension. After injection, aripiprazole lauroxil is converted to aripiprazole through enzymatic hydrolysis. The formulation supports monthly, six-week, and two-month administration schedules, depending on the strength and dosing regimen selected. The 1,064 mg presentation is administered every two months.[1]

The product is supplied in single-dose prefilled syringes. Available strengths include:

Product	Strength	Administration interval
ARISTADA	441 mg	Monthly
ARISTADA	662 mg	Monthly
ARISTADA	882 mg	Monthly or every six weeks
ARISTADA	1,064 mg	Every two months
ARISTADA INITIO	675 mg	One-time initiation dose

ARISTADA INITIO is used with 30 mg oral aripiprazole or an established oral aripiprazole regimen to initiate ARISTADA treatment. It is not a replacement for routine maintenance dosing.[2]

The formulation strategy separates two commercial objectives. ARISTADA provides maintenance exposure over extended intervals, while ARISTADA INITIO addresses the first-dose and oral-overlap problem that can delay adoption of long-acting injectable antipsychotics.

What excipients are used in ARISTADA?

The FDA prescribing information identifies sodium chloride, polysorbate 20, sodium phosphate monobasic monohydrate, sodium phosphate dibasic anhydrous, and water for injection as inactive ingredients in ARISTADA.[1]

Excipient	Primary formulation function	Commercial relevance
Polysorbate 20	Wetting and surface stabilization of suspended particles	Supports dispersion and limits interfacial aggregation
Sodium chloride	Tonicity adjustment	Helps control injection tolerability and suspension properties
Sodium phosphate monobasic monohydrate	Buffer component	Supports pH control
Sodium phosphate dibasic anhydrous	Buffer component	Complements phosphate buffering system
Water for injection	Aqueous vehicle	Enables parenteral administration

The commercial value of these excipients comes from their interaction with the active pharmaceutical ingredient and process conditions. A supplier cannot generally substitute a different grade based only on compendial compliance. Particle-size distribution, endotoxin control, bioburden, peroxide content, trace metals, container compatibility, and lot-to-lot consistency can affect product performance.

Polysorbate 20 is particularly relevant because surfactant degradation can generate peroxides and other degradants. For a long-acting injectable, those impurities can affect chemical stability, particle behavior, and regulatory comparability. Excipient suppliers with documented control of oxidation, residual impurities, and pharmaceutical-grade supply have a stronger position than commodity suppliers.

How does ARISTADA use excipients to control depot performance?

ARISTADA's release profile is driven primarily by the aripiprazole lauroxil prodrug and its particulate properties. The excipients support, rather than independently determine, the depot mechanism.

The principal formulation challenges are:

1. Maintaining a stable suspension during storage.
2. Achieving adequate syringeability and needle delivery.
3. Preventing excessive particle aggregation or settling.
4. Controlling injection-site tolerability.
5. Preserving dose uniformity across the syringe.
6. Maintaining performance after shipping and temperature excursions.

Polysorbate 20 improves wetting of hydrophobic drug particles in the aqueous vehicle. Phosphate salts control pH, while sodium chloride contributes to isotonicity. These functions are conventional, but their acceptable operating ranges are narrow in a high-dose intramuscular suspension.

The 1,064 mg dose increases the importance of suspension homogeneity and delivery mechanics. A formulation that performs adequately at 441 mg may require different mixing, filling, hold-time, and resuspension controls at the higher dose. The commercial product therefore relies on process knowledge, not only on the qualitative excipient composition.

What formulations are protected by ARISTADA intellectual property?

ARISTADA's intellectual property position is expected to include several layers:

• Composition and prodrug patents covering aripiprazole lauroxil.
• Long-acting injectable formulation patents.
• Particle-size, suspension, or release-control claims.
• Dosing-regimen and initiation-method patents.
• Manufacturing and process-control know-how.
• Device and prefilled-syringe configuration.
• ARISTADA INITIO-related formulation and administration claims.

The most defensible commercial protection is usually the combination of drug substance, particulate attributes, depot performance, dose strength, and administration schedule. A competitor may avoid a narrow excipient claim while still facing difficulty reproducing the same pharmacokinetic profile and injection characteristics.

Publicly available FDA Orange Book data should be used for the operative list of patents and expiration dates because listed patents can change through patent corrections, pediatric extensions, terminal disclaimers, or FDA updates.[3] Patent families associated with aripiprazole lauroxil and its injectable products have been assigned principally to Alkermes entities. The relevant analysis must separate patents covering the active prodrug from patents covering ARISTADA's specific presentation and dosing regimen.

A patent search should screen at least:

Patent category	Main risk to a competing injectable
Aripiprazole lauroxil composition	Blocks use of the prodrug itself
Injectable depot formulation	Blocks a suspension with specified release characteristics
Particle engineering	May capture size, morphology, or surface properties
Dosing regimen	May affect monthly, six-week, or two-month use
Initiation method	May affect oral overlap and INITIO-style initiation
Device and presentation	May affect prefilled syringe commercialization
Manufacturing process	May limit scale-up or equivalent product manufacture

When does ARISTADA lose exclusivity?

ARISTADA's FDA approval date was October 5, 2015. Its three-year new-chemical-entity-related marketing exclusivity period expired in 2018 if measured from the original approval framework applicable to the product, while any later three-year exclusivity associated with a supplemental approval would depend on the specific FDA approval and exclusivity record.[1][3]

Patent expiry is separate from regulatory exclusivity. A competitor can face continued patent barriers after regulatory exclusivity has ended. Conversely, expiration of one listed patent does not necessarily clear all formulation, method-of-use, process, or device claims.

ARISTADA does not use biosimilar exclusivity rules because aripiprazole lauroxil is a small-molecule drug product rather than a biologic. A competing product would generally be evaluated through the abbreviated new drug application pathway if it could meet applicable pharmaceutical equivalence and bioequivalence requirements, although the complex injectable formulation may create technical and regulatory challenges.

What is the Orange Book status of ARISTADA?

ARISTADA is an FDA-approved small-molecule prescription drug listed in the Orange Book under Alkermes, Inc.'s NDA 207533. The Orange Book is the controlling public source for listed patents, patent-use codes, and relevant exclusivity entries.[3]

The commercial implications are:

• A generic applicant may file a Paragraph IV certification against a listed patent.
• A Paragraph IV notice can trigger patent litigation by the NDA holder.
• A timely patent-infringement action can create a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory conditions.
• A generic applicant may pursue a non-infringement or invalidity position against composition, formulation, method-of-use, or device-related claims.
• The filing strategy may depend on whether the applicant seeks approval for every strength and dosing regimen.

Because ARISTADA is an injectable suspension, an ANDA applicant must address more than active ingredient identity. The applicant must demonstrate appropriate quality, strength, purity, sterility, particulate control, syringe performance, and bioequivalence. FDA approval of a generic long-acting injectable does not require the product to use the same non-active ingredients in every case, but differences must not affect safety, efficacy, or performance.

Which companies are challenging ARISTADA?

Publicly verified market entry depends on FDA approval records, Paragraph IV litigation dockets, and Orange Book updates. A complete challenger list cannot be established from the product label alone. The relevant competitive set includes:

• Generic injectable manufacturers with experience in depot suspensions.
• Specialty pharmaceutical companies developing long-acting antipsychotics.
• Companies with aripiprazole products seeking an extended-release injectable position.
• Contract development and manufacturing organizations with sterile suspension capabilities.
• Device manufacturers developing alternative prefilled syringe systems.

The most credible challenger would need an integrated formulation, sterile manufacturing, device, regulatory, and patent strategy. A conventional oral generic company without depot-injection capabilities would face a higher development burden.

What commercial opportunities exist for ARISTADA excipients?

Excipient supply and qualification

The immediate opportunity is supply of high-quality polysorbate 20, phosphate salts, sodium chloride, and water-for-injection systems. Suppliers can compete through:

• Low-peroxide polysorbate grades.
• Strong traceability and dual-site supply.
• Low-bioburden and low-endotoxin controls.
• Stability data in contact with aripiprazole lauroxil.
• Regulatory support for DMF and change-control packages.
• Packaging systems that reduce oxidation and contamination risk.

For a marketed sterile injectable, supplier qualification can create long-lived revenue because formulation changes may require comparability studies, stability work, and regulatory assessment.

Reformulation and line extension

Potential product-development opportunities include:

• Lower-volume injections.
• Improved resuspension before administration.
• Reduced injection-site discomfort.
• Longer intervals beyond two months.
• Alternative needle or syringe configurations.
• Room-temperature handling improvements.
• More convenient initiation regimens.
• Combination kits containing initiation and maintenance doses.

Each opportunity must preserve the pharmacokinetic profile and avoid creating new injection-site or immunogenicity concerns.

Manufacturing and process technology

The strongest opportunity may be process technology rather than a novel excipient. Relevant capabilities include:

• Controlled precipitation or particle formation.
• Aseptic suspension processing.
• High-shear and low-shear mixing optimization.
• In-line particle-size monitoring.
• Suspension hold-time validation.
• High-dose syringe filling.
• Automated resuspension and delivery testing.
• Container-closure integrity testing.

A CDMO able to manufacture sterile, high-dose, long-acting suspensions at commercial scale can become a strategic partner for generics, lifecycle products, or regional licensees.

How does ARISTADA compare with competing long-acting antipsychotics?

ARISTADA competes with Abilify Maintena, which contains aripiprazole monohydrate, and with long-acting products containing paliperidone, risperidone, and olanzapine. The primary differentiation is dosing flexibility.

Product	Active ingredient	Typical dosing concept	Key commercial distinction
ARISTADA	Aripiprazole lauroxil	Monthly to every two months	Multiple maintenance intervals and INITIO initiation
Abilify Maintena	Aripiprazole monohydrate	Monthly	Same pharmacologic class with a different depot technology
Invega Sustenna	Paliperidone palmitate	Monthly	Broad use in long-acting antipsychotic practice
Invega Trinza	Paliperidone palmitate	Every three months	Longer maintenance interval
Perseris	Risperidone	Monthly	Subcutaneous delivery and in situ depot approach

ARISTADA's excipient system is less commercially distinctive than its prodrug, particle engineering, dosing schedule, and initiation strategy. Competing products can use different excipients while still competing for the same adherence and maintenance-treatment market.

What generic entry risks exist for ARISTADA?

Generic entry risk is moderate to high in the long term but technically more difficult than for an oral aripiprazole product. The main risk factors are:

• Expiration or invalidation of core prodrug patents.
• Successful Paragraph IV challenges.
• Demonstration of bioequivalence for a long-acting suspension.
• Ability to match injection-site performance.
• Availability of sterile manufacturing capacity.
• Acceptance of an alternative excipient system.
• Physician willingness to switch stable patients.
• Payer pressure after approval of an equivalent product.

The main barriers are formulation development, clinical pharmacokinetic modeling, sterile scale-up, and patent litigation. An authorized generic or settlement-based launch could enter earlier than an independent generic if Alkermes chooses a commercial arrangement.

What licensing deals could expand ARISTADA's commercial reach?

Potential licensing structures include:

• Regional commercialization licenses.
• Co-development of a lower-volume or longer-interval formulation.
• Supply agreements for sterile suspension manufacture.
• Device partnerships for next-generation injection systems.
• Excipient and process licenses.
• Generic settlement agreements involving delayed entry.
• Co-promotion agreements targeting public-sector or institutional markets.

Alkermes has historically retained a substantial role in ARISTADA commercialization. Any licensing analysis should distinguish rights to ARISTADA, ARISTADA INITIO, aripiprazole lauroxil intellectual property, regional marketing rights, and manufacturing rights. A license to sell the product does not necessarily confer rights to use the underlying formulation process or patent-protected manufacturing technology.

How strong is the ARISTADA patent estate?

The estate is strongest where multiple claim types overlap: aripiprazole lauroxil composition, injectable depot formulation, dosing interval, initiation method, and manufacturing process. It is weaker if protection depends only on broad excipient claims because polysorbate 20, phosphate buffer, sodium chloride, and water for injection are widely used pharmaceutical ingredients.

Commercial strength depends on five factors:

1. The number of unexpired Orange Book-listed patents.
2. The breadth of claims covering a pharmaceutically equivalent suspension.
3. The ability to prove infringement through product testing or regulatory filings.
4. The vulnerability of the patents to obviousness and written-description attacks.
5. The availability of non-infringing alternative particle and dosing designs.

The excipient list alone is unlikely to prevent competition. The integrated formulation and process platform is more important.

Key Takeaways

• ARISTADA uses a conventional aqueous excipient system containing polysorbate 20, phosphate salts, sodium chloride, and water for injection.
• The commercial performance of the formulation depends on particle engineering, suspension stability, injectability, and depot release.
• ARISTADA's main differentiation is the aripiprazole lauroxil prodrug, dosing flexibility, prefilled presentation, and ARISTADA INITIO initiation strategy.
• Excipient suppliers can compete through impurity control, sterile quality, regulatory support, and supply reliability.
• Generic entry is more difficult than oral aripiprazole entry because of long-acting injectable bioequivalence and manufacturing requirements.
• The most valuable intellectual property is likely to reside in the combined prodrug, formulation, particle, dosing, process, and device estate rather than in the individual excipients.
• ARISTADA is not subject to biosimilar substitution rules because it is a small-molecule drug product.

FAQs

Can a generic ARISTADA use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the formulation remains acceptable for safety, performance, quality, and bioequivalence. Differences in surfactant grade, buffer composition, or tonicity can require extensive comparative testing.

Is polysorbate 20 the main patent barrier for ARISTADA?

No. Polysorbate 20 is a common pharmaceutical excipient. The principal barriers are more likely to involve aripiprazole lauroxil, depot particle properties, release performance, dosing regimens, manufacturing processes, and device presentation.

Does ARISTADA have biosimilar competition?

No. ARISTADA is a small-molecule injectable drug, so potential competitors would generally pursue an ANDA or another applicable small-molecule pathway rather than a biosimilar application.

Can ARISTADA be reformulated for subcutaneous injection?

A subcutaneous version would be a new product-development program. It would require evidence addressing local tolerability, absorption, pharmacokinetics, dose delivery, device performance, and regulatory comparability.

Does ARISTADA INITIO reduce the commercial value of routine ARISTADA dosing?

No. ARISTADA INITIO supports initiation and reduces reliance on prolonged oral overlap. Its commercial value is linked to improving treatment start and continuation, while routine maintenance revenue remains tied to ARISTADA injections.

References

1. U.S. Food and Drug Administration. (2024). ARISTADA (aripiprazole lauroxil) extended-release injectable suspension: Prescribing information. Alkermes, Inc.

2. U.S. Food and Drug Administration. (2024). ARISTADA INITIO (aripiprazole lauroxil) extended-release injectable suspension: Prescribing information. Alkermes, Inc.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. Alkermes plc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.